HMGB1 and Lymphadenopathy: Our anti-HMGB1 mAb failed to improve lymphadenopathy; nevertheless, it demonstrated therapeutic potential against albuminuria in lupus nephritis by inhibiting neutrophil recruitment and NETs without altering autoantibody production.